Corient Private Wealth
QTTB icon

Corient Private Wealth’s Q32 Bio QTTB Stock Holding History

Corient Private Wealth’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-556
Closed -$6.08K – 2379
2023
Q4 		$6.08K Buy
+556
New +$8.13K ﹤0.01% 2242

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Corient Private Wealth's QTTB Position: Q1 2024 in Review

Corient Private Wealth sold out of Q32 Bio (QTTB) in Q1 2024, closing a stake of 556 shares — an estimated $6.08K sold.

Corient Private Wealth first reported a position in QTTB in Q4 2023 and held it in 1 quarter. The position peaked at $6.08K in Q4 2023. 39 funds tracked by Wall St. Rank hold QTTB as of Q1 2024.

  • Corient Private Wealth reported no remaining Q32 Bio position as of Q1 2024 after selling out during the quarter.
  • Corient Private Wealth sold 556 Q32 Bio shares in Q1 2024, an estimated $6.08K.
  • Corient Private Wealth first reported a position in Q32 Bio in Q4 2023 and held it in 1 quarter.
  • Corient Private Wealth's Q32 Bio position peaked at $6.08K in Q4 2023.
  • 39 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2024.

Based on Corient Private Wealth's 13F filing for Q1 2024, filed 9 May 2024.